News
Molecular Test Further Helps Personalize Rheumatoid Arthritis Care
Author: Bret Stetka, MD Results from a new study suggest that a simple blood test can identify patients who are...
New Partnership Delivers Precision Medicine to Pharmacy Benefits Managers
Specialty drug spending contributes the largest share to rising healthcare costs. To make matters worse, in the case of rheumatoid...
Can a Blood-Based Test Predict TNFi Nonresponse in RA?
Richard Mark Kirkner via Medscape A blood test that uses a patient’s unique genetic signature has shown some ability to...
In RA, New Molecular Signature Test Confirms Who Won’t Respond to Anti-TNF Therapy During Any Point in Therapeutic Journey
Q&A with Erin Connolly-Strong PhD, Head Medical Affairs Scipher Medicine via BiopharmaDive Multiple classes of drugs exist for treating rheumatoid...
Scipher Medicine Increases Patient Access for PrismRA by Expanding Intended Use in Autoimmune Patients
Expanded intended use for the blood test validated in Network-004 study. Now, most rheumatoid arthritis patients can be tested at...
Scipher Medicine Announces PrismRA Met Primary and Secondary Endpoints in Prospective Observational Study Predicting Inadequate Response to World’s Largest-Selling Drug Class, TNFi
Blood Test Predicts TNFi Response in Patients Both Naïve to and Experienced with Therapy Providers Can Access Patient-Specific Data for...
Scipher Medicine Presents New Data at the European League Against Rheumatism (EULAR) 2021 Further Validating PrismRA Test
• Molecular signature test predicts likelihood of non-response to adalimumab or etanercept, two of the world’s most expensive medications, in...
Scipher Medicine Announces $82 Million Financing
-aMoon and Northpond Ventures led the round.-Additional investors include Echo Health Ventures, Khosla Ventures and Alumni Ventures.-Financing will support commercialization...
WellDyne Partners with Scipher Medicine to Improve Patient Outcomes and Lower Costs for Rheumatoid Arthritis Care
New PrismRA® blood test enables providers to identify optimal approach to rheumatoid arthritis treatment FEBRUARY 11, 2021 – WALTHAM, MA...
Scipher Medicine Brings Precision Medicine Platform to Patient-Centered MIT Initiative
First-Of-Its-Kind Lab Test Helps Guide Targeted Treatment Decisions in Rheumatoid Arthritis FEBRUARY 3, 2021 – WALTHAM, MA – Scipher Medicine, a...